



Effect of Adjuvant Chemotherapy is Responsible for Decreasing Segmental and Total BMD in BC Postmenopausal Women

Laxmi Samhitha Bontha
Department of oncological Gynecology, Medical University of Lodz, USA

*Corresponding Author: Laxmi Samhitha Bontha, Department of oncological Gynecology, Medical University of Lodz, USA

Received Date: March 12, 2022; Accepted Date: March 30, 2022; Published Date: April 02, 2022

Citation: Laxmi Samhitha Bontha, Effect of Adjuvant Chemotherapy is Responsible for Decreasing Segmental and Total BMD in BC Postmenopausal Women, J Women Health Care Research and Reports

Copyright: © 2022 Laxmi Samhitha Bontha, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Bone cancer (BC), which forms in tubes and lobules of bone apkins, occurs in both men and women, although manly bone cancer is rare. It's the most common cause of cancer death among women worldwide; its prevalence rates being high in advanced countries whereas rates in developing countries and in Japan are low but adding. BC accounts for 37.6 of all reported excrescences in Egyptian ladies, with an age- acclimated prevalence rate of 49.6 per,000 ladies. BC, prostate cancer, and multiple myeloma have particularly shown strong association with cadaverous metastases and related bone loss, performing in fracture, hypercalcemia, pain, and declines in mobility and performance status .

Keywords: Chemotherapy; bone turnover; bone mineral density; osteoporosis; dual-energy X-ray absorptiometry; multivariate regression analysis

Introduction

Bone cancer (BC), which forms in tubes and lobules of bone apkins, occurs in both men and women, although manly bone cancer is rare (1). It's the most common cause of cancer death among women worldwide; its prevalence rates being high in advanced countries whereas rates in developing countries and in Japan are low but adding. BC accounts for 37.6 of all reported excrescences in Egyptian ladies, with an age- acclimated prevalence rate of 49.6 per,000 ladies (2). BC, prostate cancer, and multiple myeloma have particularly shown strong association with cadaverous metastases and related bone loss, performing in fracture, hypercalcemia, pain, and declines in mobility and performance status (4).

Although adjuvant chemotherapy represents a significant advance in the operation of cases with BC, which has dragged their survival by dwindling the systemic relapse, it causes a significant reduction in their bone mineral viscosity (BMD) (2). therefore, women with BC are at increased threat for the development of osteoporosis and cadaverous fractures, giving rise to significant morbidity and some mortality (3), as a consequence of aromatase inhibition or chemotherapyinduced ovarian failure (5). Exemestane and anastrozole, two chemotherapeutic aromatase impediments, have been shown to directly inhibit osteoclast isolation and bone resorption labels leading to osteoporosis in postmenopausal women with non-metastatic bone cancer (NMBC) (6). The bone resorptioncross-linked carboxyloptide of collagen type I (CTX- I) combined with BMD measures, can be used for assessing bone health status in postmenopausal women (8).

The objects of this study were to probe biochemical labels of bone conformation and resorption as well as segmental and total BMD in NMBC postmenopausal Egyptian women ahead and after entering a 6- cycles adjuvant chemotherapy treatment protocol.

Styles

Cases and material

The study population was comprised of 100 postmenopausal women (mean age (\pm SD) 55.06 \pm 4.78 time and body mass indicator (BMI) 38.28 \pm 4.13 kg/ m²) with recently diagnosed T1-3 N0- 2 M0 BC, who were studied longitudinally ahead and after entering 6- cycles of a three- medicine combination protocol

containing Cyclophosphamide (600 mg/ m²), Adriamycin (40 mg/ m²), and 5-

Fluorouracil (600 mg/ m²) (CAF), as detailed away (10). Actors were signed from the Department of Cancer Management and Research, Medical Research Institute, Alexandria University, Alexandria, Egypt; where they were rehabilitated for opinion and/ or treatment; and were appertained to the Medical Biophysics and Chemical Pathology Departments, Medical Research Institute, Alexandria University, Alexandria, Egypt for posterior bone densitometric measures and blood biochemical analysis, independently. The study was conducted in agreement with ethical guidelines of the 1975 protestation of Helsinki and the Ethics Committee of the Medical Research Institute, Alexandria University approved the study protocol.

All party women were asked to freely bestow to the study protocol and handed an inked informed concurrence previous to their registration.

Clinical staging of BC was carried out according to the recent guidelines of the AJCC on base of a detailed physical examination, imaging studies, operative findings and pathologic examination of the bone and other apkins (11). Rejection criteria from the study protocol were the following (1) serum creatinine lesser than 150 mmol/ L;(2) peptic ulcer;(3) hysterectomy or bilateral oophorectomy;(4) osteoporosis;(5) undressed hypothyreosis;(6) bisphosphonate, calcitonin or peroral steroid remedy;(7) gestation or lactation; and (8) other malice.

All party women were canvassed regarding general health, bone pangs, history of fractures, specifics, and menopausal status and were subordinated to a complete physical examination stressing on bone, joints, and neurological examination. The following analyses were carried out, using standard styles.

Blood biochemical analyses

Fasting blood samples were collected from all party women to determine serum situations of erythrocyte sedimentation rate(ESR, mm/ hr)(12) and total calcium(Ca, mg/ dl)(13) using a semi-automatic chemical analyzer(Olympus AU 400, Olympus Life and Material Science, Europe GmbH, Hamburg, Germany); osteocalcin(OC, ng/ ml)(14), 25- hydroxyvitamin D(25- VitD,



pg/ ml)(15), parathyroid hormone(PTH, pg/ ml)(16) and
excretion marker CA15- 3(U/ ml)(17) by chemiluminescence
fashion(Immulite 1000, Siemens Healthcare DiagnosticsInc.,
Flanders, NJ, USA); and total alkaline phosphatase(peak, U/ l),
bone specific alkaline

phosphatase(S.ALP, $\mu\text{g/ L}$)(16) and carboxyloleptide of
collagen type I(CTx- I, ng/ ml)(18) by ELISA fashion(ELISA ELx
800, Bio-Tek InstrumentsInc., Winooski, UT, USA).

Imaging, body- composition and bone densitometric measures
Imaging studies were carried out for all party women using
casketX-ray, abdominal and pelvic ultrasound and
mammography. Demographic and body- composition variables
were also measured for all party women. Specifically, body weight
(kg)(actors clothed in undergarments, bare bases) was measured
using a digital scale sensitive to the nearest0.01 kg(Electronic
Body Scale, TCS – 200 – RT, China). Height (m) was measured
using a stadiometer. Segmental (i.e., head, arms, box, caricatures,
chine, pelvis and legs) and total bone mineral content (BMC) and
BMD, as well as fat mass (FM), spare bone-free mass (LBFM) and
towel bone-free mass (TBFM) were assessed using a Binary-
energyX-ray Absorptiometry (DXA) total body scanner (Lunar
DXP Pro, GE Health Care, USA), as detailed before by our group
(19- 22).

Statistical analysis

Data analysis was carried out using the StatView ® statistical
software package (SAS InstituteInc., Cary, NC, USA). Descriptive
statistics were calculated for the mean \pm SD of all applicable
variables and their frequency distributions were examined.
Analysis of the nonstop variables showed them to be typically
distributed. Paired Student's t- test of significance was used to
compare differences before and after adjuvant chemotherapy for
colorful variables. Differences were considered to be significant
only if p values were lower than0.05. likewise, multivariate direct
retrogression analysis was performed to examine the
interrelations among demographic variables and segmental and
total BMD for NMBC women using simple and partial correlation
portions. vaticination equations grounded on two independent
variables (i.e., Age and BMI) were developed and their accretive
correlation portions (R) and standard error of estimation (SEE)
were calculated, as detailed away (22).

Results

Segmental and total BMC and BMD, accordingly, total T- and Z-
Scores, were all significantly ($p<0.05$) lower after chemotherapy
as compared to their situations before chemotherapy.
Biochemical analysis Only PTH serum situations were
significantly advanced after chemotherapy in comparison with its
situations before chemotherapy.

Discussion

Osteoporosis is a global public health concern presently affecting
further than 200 million people worldwide, about 80 of them are
women (23). Not only cases with cancer may be at threat for
primary osteoporosis, but also for secondary osteoporosis due to
cancer curatives; which may alter the gonadal function and
negatively affect bone development (24- 27). BMD testing is
considered largely effective for establishing an opinion of
osteoporosis and covering its progression, since an inverse
relationship exists between BMD and unborn fracture threat.
BMD is expressed as a T- or Z- Score, which are the standard
divagation of BMD from the anticipated BMD for a youthful
grown-up or an age- matched normal population of the
same Coitus, independently.

Although, data of body- composition (i.e., FM, LBFM, and TBFM)
were similar before and after chemotherapy segmental and total
BMC and BMD distribution were significantly ($p<0.05$) lower
after chemotherapy in comparison with their situations before
chemotherapy. Accordingly, total T- and Z- Scores after
chemotherapy were also significantly ($p<0.001$) lower than those
before chemotherapy, attesting that bone loss was directly
related to treatment with adjuvant chemotherapy. In line with
this, numerous studies reported that adjuvant chemotherapy may
beget a rapid-fire bone loss, adding the threat of osteoporosis for
pre- and postmenopausal women with BC latterly in life (1). It has
been shown that bone loss with aging occurs because
hypogonadism may progress to primary osteoporosis. still,
secondary osteoporosis due to cancer curatives- convinced bone

loss results from other factors (e.g., habitual conditions, nutritive
scarcities, medicines,etc.) that negatively alter bone redoing. Both
cases beget elevation of PTH situations, lesser bone resorption
than conflation, bloodied neuromuscular functioning, and
increased threat for cascade and fractures (25- 27).

Biochemical analysis showed that, albeit similar situations of
serum Ca and 25- VitD, both peak andS.ALP were significantly
lower after chemotherapy as compared to their original
situations before chemotherapy. CTx- I situations were also
significantly lower after chemotherapy, denoting a condition of
dropped bone resorption inpost-chemotherapy NMBC women
Although both labels of bone conformation and resorption were
significantly lower after chemotherapy as compared to their
situations before chemotherapy, accordingly denoting a lower
bone development exertion, which was substantiated by the
significantly lower segmental and total BMD for
postchemotherapy NMBC women In line with this, Greep et al.,(1)
(25) preliminarily reported that postmenopausal women with
early BC who entered adjuvant chemotherapy had lower BMD in
comparison with their counterparts who didn't admit any
chemotherapy. also, Rodríguez- Rodríguez et al.,(1), had also
preliminarily detected significant diminishments in BMD at
lumbar, trochanter, intertrochanter and total hipsterism after
adjuvant treatment for NMBC women. The significantly advanced
PTH situations after chemotherapy (i.e.,86.34 \pm 35.02vs.59.50
 \pm 27.01 pg/ ml for that before chemotherapy, $p<0.001$) may justify
the observed drop of bone conformation inpost-chemotherapy
NMBC cases as compared to their status before chemotherapy.

The use of labels of bone development for covering bone
metastases in BC and in response to remedy had been shown
before (28- 30). Chemotherapeutic aromatase impediments (e.g.,
exemestane and anastrozole) have been shown to directly inhibit
osteoclast isolation and bone resorption labels leading to
osteoporosis in postmenopausal women with early BC (6), yet
with supposedly increased bone resorption biochemical labels, as
also had been shown before (32). It has been shown that
osteoporotic bone loss and bone metastasis eventually partake a
pathophysiologic pathway that stimulates bone resorption by
adding the conformation and exertion of osteoclasts (4).
Osteolytic lesions generally seen in BC can beget severe pain,
pathologic fracture, and contraction runs of the whim-whams
root or spinal cord, as well as metabolic disturbances (e.g.,
hypercalcemia, phosphate imbalances, dislocations in acid/ base
and neurological homeostasis, and nephrolithiasis) (33).
Combined osteolytic and osteoblastic lesions, which beget
increased bone resorption through osteoclasts within
osteoblastic lesions and compensatory, secondary bone
conformation through osteoblasts within osteolytic lesions, have
been observed in BC cases (34). thus, it's advised that women
with BC who are witnessing hormonal remedy, chemotherapy,
radiation, and bisphosphonate remedy should be nearly covered
for BMD loss and cadaverous health conservation conventions
(5). It's noteworthy, current recommendations for avoiding the
cadaverous complications of BC remedy include acceptable input
of Ca and vitamin D, regular weight- bearing exercise, conclusion
of smoking, reduction in alcohol input, and bisphosphonate
treatment for those set up to be osteoporotic (34).

As a fast and nicely accurate system for constantly covering bone
health, we developed vaticination fine formulae for chine and
pelvis BMD, which are the spots most susceptible to fracture
pitfalls, together with the total BMD of NMBC women. Multiple
direct retrogression analysis showed that the covariates age and
BMI were significantly associated with BMDspine, BMD pelvis,
and BMD total singly ($R = 0.99$, $p<0.0001$ for all associations).
These equations gave estimations, which were on normal <0.70
for BMD chine, <0.30 for BMDpelvis, and <2.00 for BMD aggregate
of all actors, which didn't affect in false negative or positive
opinion of BMD status. analogous studies carried out on
postmenopausal healthy and cirrhotic Italian women (20) as well
as on Egyptian cases with β - Thalassemia Major (22) using
anthropometric variables have proven useful for the nonstop
monitoring of their bone health with similar situations of SEE. We
believe these formulae will permit the croaker

to identify cases at threat of fracture, so that preventative
strategies or treatment can be targeted towards those at topmost
fracture threat.

One of the limitations of the present study is the small sample



size, being concentrated only on NMBC women who do not have serum creatinine lesser than 150 $\mu\text{mol/L}$; peptic ulcer; hysterectomy or bilateral oophorectomy; osteoporosis; undressed hypothyroidism; bisphosphonate, calcitonin or peroral steroid remedy; gestation or lactation; and any other malice. therefore, to validate the developed formulae, there's a need to study a bigger population of BC women, conceivably extending and taking into consideration other factors like bone metastasis

Conclusions

Adjuvant chemotherapy is responsible for dwindling segmental and total BMD in BC postmenopausal women, which can be clinically estimated by the significant changes in both T- and Z-Scores as well as biochemical labels of bone development. The drop in segmental and total BMD was substantially due to significant drop in the situations of peak and S-ALP rather than an increase in CTx- I labels. therefore, measures of BMD and biochemical labels of bone conformation and resorption for BC women before starting any adjuvant chemotherapy is important to assess original status of bone health. We believe, the simple fine formulae developed on base of the two individual variables Age and BMI can be useful for aiding the clinician to constantly cover bone health status of BC cases in analogous conditions, being suitable to manage possible bone losses fleetly and efficiently.

Competing interests

The authors declare that they have no competing interests.

References

1. [Rodriguez-Rodriguez LM, Rodriguez-Rodriguez EM, Oramas-Rodriguez JM, Santolaria-Fernandez F, Llanos M, Cruz J, Martinez A, Gonzalez-Reimers E, Gomez A and Batista N. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer. *Breast Cancer Res Treat.* 2005; 93:75-83.](#)
2. [Rennert G. Breast Cancer. In: Freedman LS, Edwards BK, Ries LAG, Young JL \(Eds\). *Cancer Incidence in Four Member Countries \(Cyprus, Egypt, Israel, and Jordan\) of the Middle East Cancer Consortium \(MECC\) Compared with US SEER.* National Cancer Institute. 2006;73-81.](#)
3. [Hadji P, Ziller M, Albert US and Kalder M. Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. *Br J Cancer.* 2010; 102:645-50.](#)
4. [Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD and Smith MR. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. *J Natl Compr Canc Netw.* 2009; 7 Suppl 7:S1-29; quiz S30.](#)
5. [Hirbe A, Morgan EA, Uluckan O and Weillbaecher K. Skeletal complications of breast cancer therapies. *Clin Cancer Res.* 2006; 12:6309s-6314s.](#)
6. [Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N and Ohashi Y. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. *Oncology.* 2010; 79:376-81.](#)
7. [Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK and Delmas PD. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. *J Bone Miner Res.* 2004; 19:1250-8.](#)
8. [Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. *Clin Biochem Rev.* 2005; 26:97-122.](#)
9. [Abd-El-Moneim NA, Hussein NG, Morsi MI, El-Kohly ZA, Shaheen NE, Abou-Raoash NM and El-Sayed LH. Effect of two chemotherapeutic regimens on some biochemical and immunological parameters in breast cancer patients. *Med. Sci. Res. \(England\).* 1998; 6:301-307.](#)
10. [Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Jr., Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R and Roter D. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. *J Natl Cancer Inst.* 2001; 93:979-89.](#)
11. [Singletary SE and Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. *CA Cancer J Clin.* 2006; 56:37-47; quiz 50-1.](#)
12. [Lewis SM, Bain BI and Bates I. *Dave and Lewis Practical Hematology Textbook.* 9th Ed. Harcourt Publisher Ltd, London. 2001; 30-41.](#)
13. [Leary NO, Pembroke A and Duggan PF. Single stable reagent \(Arsenazo III\) for optically robust measurement of calcium in serum and plasma. *Clin Chem.* 1992; 38:904-8.](#)
14. [Lee AJ, Hodges S and Eastell R. Measurement of osteocalcin. *Ann Clin Biochem.* 2000; 37:432-46.](#)
15. [Ameson WL and Ameson DL. Current Methods for Routine Clinical Laboratory Testing of Vitamin D Levels. *Lab. Medicine.* 2013; 44:e38-e42.](#)
16. [Burtis C, Ashwood E and Bruns D. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics.* 4th Ed. Elsevier Saunders Company, St. Louis. 2006; 609-611.](#)
17. [Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. *Br J Cancer.* 1991; 64:154-8.](#)
18. [Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. *Osteoporos Int.* 2000; 11 Suppl 6:S66-76.](#)
19. [Mohamed EI, Maiolo C, Iacopino L, Pepe M, Di Daniele N and De Lorenzo A. The impact of body-weight components on forced spirometry in healthy italians. *Lung.* 2002; 180:149-59.](#)
20. [Casini A, Mohamed EI, Gandin C, Tarantino U, Di Daniele N and De Lorenzo A. Predicting bone mineral density of postmenopausal healthy and cirrhotic Italian women using anthropometric variables. *Dig Liver Dis.* 2003; 35:881-7.](#)
21. [Mohamed EI and Khalil ES. Bone densitometric analysis in egyptian hemodialysis patients. *Int J Biomed Sci.* 2008; 4:120-4.](#)
22. [Mohamed EI, Mahmoud GN, Khalil GI and Sallam SM. Mathematical modeling of segmental and total bone mineral density in Egyptian patients with \$\beta\$ -Thalassaemia Major. *J. Biophys. Biomed. Sci.* 2008; 1:69-74.](#)
23. [Lane JM, Serota AC and Raphael B. Osteoporosis: differences and similarities in male and female patients. *Orthop Clin North Am.* 2006; 37:601-9.](#)
24. [Mincey BA, Moraghan TJ and Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. *Mayo Clin Proc.* 2000; 75:821-9.](#)
25. [Greep NC, Giuliano AE, Hansen NM, Taketani T, Wang HJ and Singer FR. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. *Am J Med.* 2003; 114:653-9.](#)
26. [Wickham R. Osteoporosis related to disease or therapy in patients with cancer. *Clin J Oncol Nurs.* 2011; 15:E90-E104.](#)



27. [Winters-Stone KM, Dobek J, Nail L, Bennett JA, Leo MC, Naik A and Schwartz A. Strength training stops bone loss in survivors: a randomized, controlled trial. *Breast Cancer Res Treat.* 2011; **127**:447-56.](#)
28. [Fontana A and Delmas PD. Markers of bone turnover in bone metastases. *Cancer.* 2000; **88**:2952-60.](#)
29. [Lipton A, Costa L, Ali S and Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. *Semin Oncol.* 2001; **28**:54-9.](#)
30. [Oremek GM, Weis A, Sapoutzis N and Sauer-Eppel H. Diagnostic value of bone and tumour markers in patients with malignant diseases. *Anticancer Res.* 2003; **23**:987-90.](#)
31. [Watts NB. Clinical utility of biochemical markers of bone remodeling. *Clin Chem.* 1999; **45**:1359-68.](#)
32. [Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T and Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross-sectional and longitudinal evaluation. *Br J Cancer.* 2006; **95**:506-14.](#)
33. [Roodman GD. Mechanisms of bone metastasis. *N Engl J Med.* 2004; **350**:1655-64.](#)
34. [Coleman RE. Bisphosphonates: clinical experience. *Oncologist.* 2004; **9** Suppl 4:14-27.](#)

1.

Ready to submit your research? Choose Alcrut and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Alcrut, research is always in progress.

Learn more:

<https://www.alcrut.com/journals/index.php?iname=women%20health%20care%20Research%20and%20reports>



This work is licensed under creative commons attribution 4.0

To submit your article Click Here: [Submit Manuscript](#)

